Johnson & Johnson (JNJ) Stock Forecast & Price Target

$254.64 +9.76 (+3.99%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$254.38 -0.26 (-0.10%)

As of 06/26/2026 07:59 PM Eastern

Compare

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
7

Buy
20

Based on 27 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 7 have given a hold rating, and 20 have given a buy rating for JNJ.

Consensus Price Target

$256.70
0.81% Upside

According to the 27 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $256.70. The highest price target for JNJ is $285.00, while the lowest price target for JNJ is $210.00. The average price target represents a forecasted upside of 0.81% from the current price of $254.64.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Analyst Ratings Over Time

Type	Current Forecast 6/27/25 to 6/27/26	1 Month Ago 5/28/25 to 5/28/26	3 Months Ago 3/29/25 to 3/29/26	1 Year Ago 6/27/24 to 6/27/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	20 Buy rating(s)	20 Buy rating(s)	17 Buy rating(s)	7 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$256.70	$253.04	$236.91	$170.88
Forecasted Upside	0.81% Upside	9.53% Upside	-1.45% Downside	12.10% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Johnson & Johnson Stock vs. The Competition

Type	Johnson & Johnson	Medical Companies	Broader Market
Consensus Rating Score	2.74	2.29	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	0.81% Upside	723.90% Upside	14.32% Upside
News Sentiment Rating	Positive News See Recent JNJ News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/26/2026	Johnson Rice 2 of 5 stars		Set Target		$270.00	+6.84%
6/26/2026	Guggenheim 5 of 5 stars	Vamil Divan 5 of 5 stars	Boost Target	Buy	$266.00 ➝ $270.00	+7.39%
6/15/2026	Weiss Ratings 5 of 5 stars		Downgrade	Buy (B) ➝ Buy (B-)
5/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$265.00	+18.07%
4/16/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$240.00 ➝ $275.00	+15.87%
4/16/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$237.00 ➝ $246.00	+3.65%
4/15/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$283.00	+18.90%
4/15/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$265.00	+10.35%
4/15/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$220.00 ➝ $250.00	+4.11%
4/15/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$234.00 ➝ $255.00	+6.19%
SpaceX is offering you shares. Don't take them. (Ad) SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $1.75 trillion valuation and 266 times earnings, you're buying in at the most expensive IPO in history - right when institutions who got in at $800 billion need someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure Colossus can't run without - and it's still trading at a fraction of its value. Skip the IPO trap and get the backdoor ticker for free
4/15/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$253.00 ➝ $254.00	+7.02%
4/15/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$237.00 ➝ $258.00	+7.84%
4/15/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$250.00 ➝ $260.00	+8.68%
4/15/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$225.00 ➝ $251.00	+4.92%
4/15/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$240.00 ➝ $263.00	+9.93%
4/15/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$265.00 ➝ $275.00	+14.95%
4/8/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Nedelcovych Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$250.00	+5.46%
4/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$274.00 ➝ $285.00	+19.13%
3/17/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Morten Herholdt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$265.00 ➝ $280.00	+16.28%
2/19/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$180.00 ➝ $210.00	-14.76%
1/27/2026	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ilya Zubkov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$220.00	-2.28%
1/22/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
1/16/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
1/5/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
1/5/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$225.00 ➝ $240.00	+17.19%
12/11/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
7/23/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/17/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
4/24/2025	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Todd Brooks Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
10/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$215.00 ➝ $215.00	+30.70%
7/18/2024	TD Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$195.00 ➝ $185.00	+18.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:46 AM ET.

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, June 24, 2026. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

The current stock price is around $160, which may present a buying opportunity for investors looking for value in a well-established company.
Johnson & Johnson recently reported strong quarterly earnings, exceeding analyst expectations, which indicates robust financial health and operational efficiency.
The company has a solid dividend yield of 2.3%, providing a reliable income stream for investors, along with a history of increasing dividends, which reflects its commitment to returning value to shareholders.
With a return on equity of 32.60%, Johnson & Johnson demonstrates effective management and profitability, suggesting that the company is generating significant returns on shareholders' investments.
The revenue growth of 9.9% compared to the same quarter last year highlights the company's ability to expand its market presence and adapt to changing consumer needs.

Johnson & Johnson
Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

The earnings per share decreased from $2.77 in the same quarter last year to $2.70, which may raise concerns about the company's growth trajectory.
Johnson & Johnson's payout ratio is currently 61.97%, indicating that a significant portion of its earnings is being distributed as dividends, which could limit funds available for reinvestment in growth opportunities.
Potential legal challenges and regulatory scrutiny in the healthcare sector could pose risks to the company's reputation and financial stability.
Market volatility and economic uncertainties may impact consumer spending on healthcare products, affecting Johnson & Johnson's sales and profitability.
As a large multinational corporation, Johnson & Johnson may face challenges related to global supply chain disruptions, which could affect its operations and product availability.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $256.70, with a high forecast of $285.00 and a low forecast of $210.00.

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 7 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JNJ shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 0.81% based on their 12-month stock forecasts.

Over the previous 90 days, Johnson & Johnson's stock had 2 upgrades and 2 downgrades by analysts.

Johnson & Johnson has been rated by research analysts at Argus, Bank of America, Barclays, Citigroup, Daiwa Securities Group, Guggenheim, Johnson Rice, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Raymond James Financial, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Johnson & Johnson more than other "medical" companies. The consensus rating for Johnson & Johnson is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how JNJ compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Johnson & Johnson Recommendations

This page (NYSE:JNJ) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Stock Forecast & Price Target